149 related articles for article (PubMed ID: 37345529)
1. Structural and energetic insights into the selective inhibition of PKMYT1 against WEE1.
Qi X; Li G; Liu J; Mou L; Zhang Y; Guo S; Chen X; Li W
J Biomol Struct Dyn; 2024 Apr; 42(6):3010-3018. PubMed ID: 37345529
[TBL] [Abstract][Full Text] [Related]
2. Computational simulation studies on the binding selectivity of Wee1 and Checkpoint kinase 1 by molecular dynamics simulation combined with free energy calculations.
Li Y; Liu X; Zhang S; Wang L; Zhang L; Zuo Z
J Biomol Struct Dyn; 2022 Feb; 40(3):1172-1181. PubMed ID: 33016857
[TBL] [Abstract][Full Text] [Related]
3. Pharmacophore modeling, multiple docking, and molecular dynamics studies on Wee1 kinase inhibitors.
Hu Y; Zhou L; Zhu X; Dai D; Bao Y; Qiu Y
J Biomol Struct Dyn; 2019 Jul; 37(10):2703-2715. PubMed ID: 30052133
[TBL] [Abstract][Full Text] [Related]
4. Mechanistic Insights into the Mechanism of Inhibitor Selectivity toward the Dark Kinase STK17B against Its High Homology STK17A.
Liu C; Zhang Y; Zhang Y; Liu Z; Mao F; Chai Z
Molecules; 2022 Jul; 27(14):. PubMed ID: 35889528
[TBL] [Abstract][Full Text] [Related]
5. Identification of PKMYT1 inhibitors by screening the GSK published protein kinase inhibitor set I and II.
Platzer C; Najjar A; Rohe A; Erdmann F; Sippl W; Schmidt M
Bioorg Med Chem; 2018 Aug; 26(14):4014-4024. PubMed ID: 29941193
[TBL] [Abstract][Full Text] [Related]
6. Computer-aided design, synthesis and biological characterization of novel inhibitors for PKMYT1.
Najjar A; Platzer C; Luft A; Aßmann CA; Elghazawy NH; Erdmann F; Sippl W; Schmidt M
Eur J Med Chem; 2019 Jan; 161():479-492. PubMed ID: 30388464
[TBL] [Abstract][Full Text] [Related]
7. Decoding molecular mechanism of inhibitor bindings to CDK2 using molecular dynamics simulations and binding free energy calculations.
Chen J; Pang L; Wang W; Wang L; Zhang JZH; Zhu T
J Biomol Struct Dyn; 2020 Mar; 38(4):985-996. PubMed ID: 30843759
[TBL] [Abstract][Full Text] [Related]
8. Discovery of an Orally Bioavailable and Selective PKMYT1 Inhibitor, RP-6306.
Szychowski J; Papp R; Dietrich E; Liu B; Vallée F; Leclaire ME; Fourtounis J; Martino G; Perryman AL; Pau V; Yin SY; Mader P; Roulston A; Truchon JF; Marshall CG; Diallo M; Duffy NM; Stocco R; Godbout C; Bonneau-Fortin A; Kryczka R; Bhaskaran V; Mao D; Orlicky S; Beaulieu P; Turcotte P; Kurinov I; Sicheri F; Mamane Y; Gallant M; Black WC
J Med Chem; 2022 Aug; 65(15):10251-10284. PubMed ID: 35880755
[TBL] [Abstract][Full Text] [Related]
9. Decoding molecular mechanism of species-selective targeting of fungal versus human HSP90 using multiple replica molecular dynamics simulations and binding free energy calculations.
Cheng J; Yin X; Wang L; Liu X; Yang F; Zhang L; Liu T
J Biomol Struct Dyn; 2023 Oct; ():1-11. PubMed ID: 37850420
[TBL] [Abstract][Full Text] [Related]
10. A WEE1 family business: regulation of mitosis, cancer progression, and therapeutic target.
Ghelli Luserna di Rorà A; Cerchione C; Martinelli G; Simonetti G
J Hematol Oncol; 2020 Sep; 13(1):126. PubMed ID: 32958072
[TBL] [Abstract][Full Text] [Related]
11. Probing the "fingers" domain binding pocket of Hepatitis C virus NS5B RdRp and D559G resistance mutation via molecular docking, molecular dynamics simulation and binding free energy calculations.
Manjula S; Sivanandam M; Kumaradhas P
J Biomol Struct Dyn; 2019 Jun; 37(9):2440-2456. PubMed ID: 30047829
[TBL] [Abstract][Full Text] [Related]
12. Evaluating the suitability of RNA intervention mechanism exerted by some flavonoid molecules against dengue virus MTase RNA capping site: a molecular docking, molecular dynamics simulation, and binding free energy study.
Manjula S; Kumaradhas P
J Biomol Struct Dyn; 2020 Aug; 38(12):3533-3543. PubMed ID: 31514688
[TBL] [Abstract][Full Text] [Related]
13. Insight into the selective binding mechanism of DNMT1 and DNMT3A inhibitors: a molecular simulation study.
Xie T; Yu J; Fu W; Wang Z; Xu L; Chang S; Wang E; Zhu F; Zeng S; Kang Y; Hou T
Phys Chem Chem Phys; 2019 Jun; 21(24):12931-12947. PubMed ID: 31165133
[TBL] [Abstract][Full Text] [Related]
14. In silico identification of potential Hsp90 inhibitors via ensemble docking, DFT and molecular dynamics simulations.
Rezvani S; Ebadi A; Razzaghi-Asl N
J Biomol Struct Dyn; 2022; 40(21):10665-10676. PubMed ID: 34286666
[TBL] [Abstract][Full Text] [Related]
15. Structural Basis of Wee Kinases Functionality and Inactivation by Diverse Small Molecule Inhibitors.
Zhu JY; Cuellar RA; Berndt N; Lee HE; Olesen SH; Martin MP; Jensen JT; Georg GI; Schönbrunn E
J Med Chem; 2017 Sep; 60(18):7863-7875. PubMed ID: 28792760
[TBL] [Abstract][Full Text] [Related]
16. Systematic expression analysis of WEE family kinases reveals the importance of PKMYT1 in breast carcinogenesis.
Liu Y; Qi J; Dou Z; Hu J; Lu L; Dai H; Wang H; Yang W
Cell Prolif; 2020 Feb; 53(2):e12741. PubMed ID: 31837068
[TBL] [Abstract][Full Text] [Related]
17. Synthetic lethal interaction between WEE1 and PKMYT1 is a target for multiple low-dose treatment of high-grade serous ovarian carcinoma.
Benada J; Bulanova D; Azzoni V; Petrosius V; Ghazanfar S; Wennerberg K; Sørensen CS
NAR Cancer; 2023 Sep; 5(3):zcad029. PubMed ID: 37325550
[TBL] [Abstract][Full Text] [Related]
18. Molecular mechanism study of several inhibitors binding to BRD9 bromodomain based on molecular simulations.
Song LT; Tu J; Liu RR; Zhu M; Meng YJ; Zhai HL
J Biomol Struct Dyn; 2019 Jul; 37(11):2970-2979. PubMed ID: 30058436
[TBL] [Abstract][Full Text] [Related]
19. Molecular simulation studies on the binding selectivity of 2-anilino-4-(thiazol-5-yl)-pyrimidines in complexes with CDK2 and CDK7.
Chohan TA; Qian HY; Pan YL; Chen JZ
Mol Biosyst; 2016 Jan; 12(1):145-61. PubMed ID: 26565382
[TBL] [Abstract][Full Text] [Related]
20. Molecular dynamics simulations provide insights into the origin of gleevec's selectivity toward human tyrosine kinases.
Wang L; Zheng G; Liu X; Ni D; He X; Cheng J; Lu S
J Biomol Struct Dyn; 2019 Jul; 37(10):2733-2744. PubMed ID: 30052122
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
